Multidisciplinary Follow-up of Patients Treated for Malignant Hematological Disease

Aalborg University Hospital300 enrolled

Overview

The aim of this study is to adjust and test an existing internet-based tool for collecting patient-reported outcome measures and to use the internet-based tool in an multidisciplinary follow-up of patients treated for malignant hematological diseases. The patient-reported outcome measurements will be used in describing the patients' health-related quality of life (HRQoL) and to investigate whether the HRQol will increase due to participation in multidisciplinary follow-up.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Malignant Hematologic Neoplasm

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients diagnosed with malignant hematological disease; Morbus Hodgkin and B- and T-cell disease * patients followed before or after 1. line treatment * patients in stable phase \> 6 months after 1. line treatment * the patients participation in the study must be assessed and decided by the doctor responsible for the patient's course of treatment Exclusion Criteria: * Health conditions which demands close medical monitoring * conditions which compromise the ability to understand the study and submit informed consent (ex.: dementia and severe mental illness / disability) * lack of capability to fill out electronic questionnaires * poor self-care and/or compliance

Locations (1)

Aalborg University Hospital, Department of Hematology

Aalborg, Denmark

RECRUITING

Outcomes

Primary Outcomes

Health-Related Quality of Life (HRQoL) - General

Patients will be asked to electronically fill out questionnaires before each consultation. The questionnaire that will be used to measure HRQoL is SF-36. SF-36 is a generic questionnaire which can be used to assess HRQoL in the general public.

Time frame: HRQoL is assessed every 2, 3, 4 or 6 months, up to 18 months.

Health-Related Quality of Life (HRQoL) - Disease specific

Patients will be asked to electronically fill out questionnaires before each consultation. The questionnaire that will be used to measure HRQoL is EORTC C30 QLQ. EORTC C30 QLQ is a disease specific questionnaire which can be used to assess HRQoL in patients diagnosed with cancer

Time frame: HRQoL is assessed every 2, 3, 4 or 6 months, up to 18 months.

Secondary Outcomes

Symptoms of depression and anxiety

Data on symptoms of depression and anxiety will be collected before and after each consultation using an international validated questionnaire. The questionnaire which will be used is: Hospital Depression and Anxiety Scale (HADS)

Time frame: Symptoms of depression and anxiety will be assessed every 2, 3, 4 or 6 month, up to 18 months

Symptoms of hematological disease

Data on symptoms of disease will be collected before each consultation using an international validated questionnaire. The questionnaire which will be used is: Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF)

Time frame: Symptoms of disease will be assessed every 2, 3, 4 or 6 month, up to 18 months

Central Contacts

Mia Sommer, MHsc

CONTACT

0045 9766 0896 m.sommer@rn.dk

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.